Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Feb;24(1):35-40.
doi: 10.1016/j.rpor.2018.09.003. Epub 2018 Oct 11.

Survival after radiation therapy for high-grade glioma

Affiliations

Survival after radiation therapy for high-grade glioma

Joana Spaggiari Marra et al. Rep Pract Oncol Radiother. 2019 Jan-Feb.

Abstract

Background: High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy.

Aim: To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy.

Materials and methods: Data from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively.

Results: Median survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27-123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes.

Conclusions: Age, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate (p < 0.05). The estimated overall survival was 18 months (Kaplan-Meier estimator). Our results corroborated those reported in the literature.

Keywords: Anaplastic; Chemotherapy; Glioblastoma; Glioma; Radiotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Selection of subjects.
Fig. 2
Fig. 2
Kaplan–Meier graph: estimation of survival rate (survival probability × time in months) between confidence intervals.
Fig. 3
Fig. 3
Kaplan–Meier graph: estimation of survival rate Grade III – dotted vs. IV (survival probability × time in months). Updated.

References

    1. Wen P.Y., Macdonald D.R., Reardon D.A. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972. - PubMed
    1. Caroline I., Rosenthal M.A. Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis? J Clin Neurosci. 2012;19(5):633–637. - PubMed
    1. Jahangiri A., Aghi M.K. Pseudoprogression and treatment effect. Neurosurg Clin N Am. 2012;23(2):277–287. - PubMed
    1. Young R.J., Gupta A., Shah A.D. MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging. 2013;37(1):41–49. - PMC - PubMed
    1. Stupp R., Mason W.P., van den Bent M.J. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed